| Similar Articles |
|---|
 |
American Journal of Nursing
October 2009 |
Pharmacogenomics: Personalizing Drug Therapy Pharmacogenomics is a rapidly growing field of research into the ways in which genetic variation affects drug response.   |
Bio-IT World
March 2006
Kevin Davies |
Clinical Data Launches Landmark Trial Clinical Data has launched a Phase III clinical trial for the depression drug vilazodone and will concurrently develop a diagnostic test. The study could prove to be a landmark event in pharmacogenomic medicine. |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
The Motley Fool
March 3, 2010
Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
Bio-IT World
September 9, 2002
Malorye Branca |
The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
The Motley Fool
September 9, 2011
Frank Vinluan |
GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
Chemistry World
June 12, 2012
Nina Notman |
Three pronged approach puts brakes on US breast cancer The US Food and Drug Administration (FDA) has approved the use of anti-HER2 therapy Perjeta (pertuzumab) to treat patients with previously untreated HER2-positive metastatic breast cancer. |
Bio-IT World
February 18, 2004 |
The Quest for Complex Genes Genetic sleuths are homing in on genes for complex diseases with the help of new, and some not so new, tools and strategies. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
Pharmaceutical Executive
November 1, 2013
Ben Comer |
2014 Pipeline Report: The Sprint to Value Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
Pharmaceutical Executive
December 1, 2006 |
Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design. |
The Motley Fool
November 19, 2010
Brian Orelli |
Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
September 27, 2010
Brian Orelli |
Now That's What I Call a Drug That Works Seattle Genetics hits a home run -- and then some -- with its cancer drug Brentuximab vedotin. |
The Motley Fool
March 21, 2011
Brian Orelli |
Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug. |
The Motley Fool
October 12, 2010
Brian Orelli |
Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
September 23, 2010
Brian Orelli |
Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
May 17, 2010
Luke Timmerman |
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. |
Pharmaceutical Executive
December 1, 2011
Ben Comer |
Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? |
The Motley Fool
June 23, 2009
Brian Orelli |
Wonder Drug! Maybe? Get the facts before jumping on this one. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade. |
Pharmaceutical Executive
November 1, 2012 |
Pharm Exec's 2013 Pipeline Report In this year's report, Ben Comer reveals that drug approvals are up, as new discoveries in biology peel away symptomology to expose underlying causes. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
The Motley Fool
June 3, 2011
Brian Orelli |
FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
Bio-IT World
Jul/Aug 2006
Kevin Davies |
Beyond the Last Chromosome About 700 attendees gathered Beyond Genome 2006, one of Cambridge Healthtech Institute's flagship conferences, to discuss the major technology trends in postgenomic biology, including systems biology, RNAi, proteomics, and personalized medicine. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
Chemistry World
March 15, 2011
Sarah Houlton |
Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration |
The Motley Fool
August 17, 2010
Brian Orelli |
Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard. |
The Motley Fool
February 1, 2011
Brian Orelli |
Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon. |
The Motley Fool
September 2, 2011
Brian Orelli |
Delcath Wants a Do-Over You'd think a drug failing to show an effect would be the worst thing that could happen to a biotech investor, but mixed results are actually much worse. |
